EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Abstract
Authors
M. Matasar J. Sanchez Alvarez H. Parise E. Zuk D. Di Maio S. Shapouri S.W. Lin